RABINOWITZ DANIEL sold $136K of NTRA

RABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 341 shares of Natera, Inc. (NTRA) at an average of $400.05 ($388.20–$400.29, $0.14M total) across 2 trades on 2026-11-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RABINOWITZ DANIEL
Published Nov 5, 2026, 2:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 3:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

The disclosed insider sale is a routine filing with modest informational content; it is unlikely to move the stock significantly.

02

Market read

The filing provides a small data point for traders monitoring insider activity but offers limited trading impetus.

03

What to watch

The insider holds a large remaining stake (167,880 shares) indicating continued commitment.

Relevance 3/10Novelty 3/10Timing: post‑market filing on 2026‑11‑04

Background

Natera, Inc. (NTRA) is a US‑listed company specializing in non‑invasive prenatal testing and oncology diagnostics.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

SEC Form 4 shows chief legal officer sold $136K of shares via a 10b5‑1 plan.

Expected impact

likely modest pressure as the market prices the insider sell.

Evidence & confidence

The sale size is small relative to market cap and was pre‑arranged, limiting informational value.

Market effects

Minimal impact on the broader genetic testing sector.

No discernible regional effect.

Limited relevance beyond Natera shareholders.

Counterpoint

The sale could be purely liquidity‑driven and not reflect confidence issues.

Key entities

  • Rabinowitz Daniel

    Chief Legal Officer and insider who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.